And it goes on and on. Norwegian health authorities expressed concern on Saturday about cases of skin bleeding in relatively young people who received a dose of the AstraZeneca vaccine against Covid-19.
If no link has yet been established with the vaccine, “this is serious and may be a sign of a decrease in the number of platelets,” warned the Norwegian Institute of Public Health, which had already suspended the vaccine “as a precaution. Because of concerns about blood clots.
Delays in delivery
The Swedish-British group AstraZeneca has also announced further reductions in deliveries of its vaccine to the European Union, citing export restrictions. A call for discussions “as soon as possible” has been launched by five EU member countries worried about disparities in the distribution of doses.
Citing “export restrictions” for vaccines manufactured outside the EU, the Swedish-British group AstraZeneca announced that it could deliver only 100 million doses to the EU during the six months ended in June, of which only 70 million out of the 180 million initially expected in the second quarter.